Posted on June 25, 2010 by BioJobBlogger

Lilly and Walmart to Sell Co-Branded Insulin?

The once venerable drugmarker Eli Lilly & Co yesterday announced that it would co-brand its Humulin insulin product with Walmart one of the world’s largest retailers starting in mid September. According to a Lilly spokesperson the product will be sold in U.S. Wal-Mart pharmacies.

Humulin, with $1 billion in worldwide sales for Lilly last year, will be Lilly’s first co-branded product with a retail pharmacy and will replace Wal-Mart’s current Relion insulin brand. The Lilly-Walmart deal is indicative of the massive changes that are taking place in the pharmaceutical industry as generic products begin to encroach on blockbuster brand name product franchises. 

The move will undoubtedly expand the product lifecycle of Lilly’s Humulin brand given Walmart’s vast distribution channels and its gargantuan customer base.

Until next time...

Good Luck and Good Job Hunting!!!!!!

 

Tags: , , , , , , , , , , ,
Posted on April 16, 2008 by BioJobBlogger

Eli Lilly & Co. to Eliminate 500 Jobs

Eli Lilly & Co. announced today that it will eliminate 500 jobs at its manufacturing facility in Indianapolis, IN. The cuts will affect sites that manufacture active pharmaceutical ingredients for Lilly’s insulin products Humalog® and Humulin® and its osteoporosis medicine Forteo®.

Lilly is offering incentive packages for those employees who voluntarily leave the company. The company has already reduced its global headcount by twelve percent or about 5,500 people since 2004.

Times are tough and getting tougher each day in pharma land. Buckle up–its going to be a rough ride for jobseekers in the pharmaceutical and biotechnology industries.

Until next time….

Good Luck and Good Job Hunting (avoid Indianapolis, who wants to be a Hoosier anyway?)

Tags: , , , , , , , , , , ,